Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [ 11C]choline?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 11, 2011, Pages 1964-1966

  Giovacchini, Giampiero ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHOLINE C 11; FLUORINE 18; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN;

CANCER PATIENT; CHOLINE UPTAKE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG WITHDRAWAL; HORMONE SENSITIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NOTE; PREDICTOR VARIABLE; PROSTATE CANCER; PROSTATECTOMY;

ANDROGEN ANTAGONISTS; ANDROGENS; CHOLINE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 80255137090     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1926-6     Document Type: Note

References (26)

1. EA Singer DJ Golijanin EM Messing 2008 Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? Can J Urol 15 4381 4387 19046491
2. FJ Bianco Jr 2008 Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era Urol Oncol 26 408 414 18593619 10.1016/j.urolonc.2007.11.002 1:CAS:528:DC%2BD1cXnvVyjurg%3D (Pubitemid 351885376)
3. 11C- choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011- 1867-0.
4. TR DeGrado RE Coleman S Wang SW Baldwin MD Orr CN Robertson, et al. 2001 Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer Cancer Res 61 110 117 11196147 1:CAS:528:DC%2BD3MXlsl2lsA%3D%3D (Pubitemid 32095708)
5. A De Waele S Van Binnebeek FM Mottaghy 2010 Response assessment of hormonal therapy in prostate cancer by [11C]choline PET/CT Clin Nucl Med 35 701 703 20706046 10.1097/RLU.0b013e3181e9faf5
6. M Picchio C Messa C Landoni L Gianolli S Sironi M Brioschi, et al. 2003 Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography J Urol 169 1337 1340 12629355 10.1097/01.ju.0000056901.95996.43 1:CAS:528:DC%2BD3sXhvFahs7o%3D (Pubitemid 36323779)
7. IJ de Jong J Pruim PH Elsinga W Vaalburg HJ Mensink 2003 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 32 38 12814672 10.1016/S0302-2838(03)00207-0 (Pubitemid 36741372)
8. M Cimitan R Bortolus S Morassut V Canzonieri A Garbeglio T Baresic, et al. 2006 [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 1387 1398 16865395 10.1007/s00259-006-0150-2 (Pubitemid 44885404)
9. L Rinnab NM Blumstein FM Mottaghy RE Hautmann R Kufer K Hohl, et al. 2007 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer BJU Int 99 1421 1426 17355373 10.1111/j.1464-410X.2007.06776.x 1:CAS:528:DC%2BD2sXotFansL0%3D (Pubitemid 47164799)
10. P Castellucci C Fuccio C Nanni I Santi A Rizzello F Lodi, et al. 2009 Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy J Nucl Med 50 1394 1400 19690023 10.2967/jnumed.108.061507
11. T Hara A Bansal TR DeGrado 2006 Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells Nucl Med Biol 33 977 984 17127170 10.1016/j.nucmedbio.2006.08.002 1:CAS:528:DC%2BD28Xht1Cls7%2FF (Pubitemid 44791951)
12. Emonds KM, Swinnen JV, van Weerden WM, Vanderhoydonc F, Nuyts J, Mortelmans L, et al. Do androgens control the uptake of (18)F-FDG, (11)C-choline and (11)C-acetate in human prostate cancer cell lines? Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1861-6.
13. G Giovacchini M Picchio E Coradeschi V Scattoni V Bettinardi C Cozzarini, et al. 2008 [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy Eur J Nucl Med Mol Imaging 35 1065 1073 18200444 10.1007/s00259-008- 0716-2 1:CAS:528:DC%2BD1cXlvVClt78%3D
14. J Nakashima Y Imai M Tachibana S Baba K Hiramatsu M Murai 1997 Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging Cancer 80 237 241 9217036 10.1002/(SICI)1097-0142(19970715)80:2<237::AID-CNCR11>3.0.CO;2-V 1:STN:280:DyaK2szmtVSjug%3D%3D (Pubitemid 27282317)
15. JV Swinnen G Verhoeven 1998 Androgens and the control of lipid metabolism in human prostate cancer cells J Steroid Biochem Mol Biol 65 191 198 9699873 10.1016/S0960-0760(97)00187-8 1:CAS:528:DyaK1cXkvVKqsr8%3D (Pubitemid 28335606)
16. UG Mueller-Lisse MG Swanson DB Vigneron H Hricak A Bessette RG Males, et al. 2001 Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging Magn Reson Med 46 49 57 11443710 10.1002/mrm.1159 1:CAS:528:DC%2BD3MXltlShsr0%3D (Pubitemid 32592138)
17. M Yoshimoto A Waki A Obata T Furukawa Y Yonekura Y Fujibayashi 2004 Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate Nucl Med Biol 31 859 865 15464387 10.1016/j.nucmedbio.2004.05.002 1:CAS:528:DC%2BD2cXotFClsr8%3D (Pubitemid 39297683)
18. AJ Breeuwsma J Pruim MM Jongen AJ Suurmeijer W Vaalburg RJ Nijman, et al. 2005 In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer Eur J Nucl Med Mol Imaging 32 668 673 15765234 10.1007/s00259-004-1741-4 (Pubitemid 40897489)
19. M Farsad R Schiavina P Castellucci C Nanni B Corti G Martorana, et al. 2005 Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis J Nucl Med 46 1642 1649 16204714 1:CAS:528:DC%2BD28XitVGlt74%3D (Pubitemid 46211588)
20. M Souvatzoglou G Weirich S Schwarzenboeck T Maurer T Schuster RA Bundschuh, et al. 2011 The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration Clin Cancer Res 17 3751 3759 21493868 10.1158/1078-0432.CCR-10-2093
21. G Giovacchini M Picchio E Coradeschi V Bettinardi L Gianolli V Scattoni, et al. 2010 Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy Eur J Nucl Med Mol Imaging 37 301 309 19756592 10.1007/s00259-009-1253-3
22. P Castellucci C Fuccio D Rubello R Schiavina I Santi C Nanni, et al. 2011 Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 38 55 63 20848281 10.1007/s00259-010- 1604-0
23. DB Husarik R Miralbell M Dubs H John OT Giger A Gelet, et al. 2008 Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 253 263 17926036 10.1007/s00259-007-0552-9
24. BJ Krause M Souvatzoglou M Tuncel K Herrmann AK Buck C Praus, et al. 2008 The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 18 23 17891394 10.1007/s00259-007-0581-4 1:CAS:528:DC%2BD2sXhsVSmtLbO (Pubitemid 350234152)
25. G Giovacchini M Picchio V Scattoni R Garcia Parra A Briganti L Gianolli, et al. 2010 PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy Eur J Nucl Med Mol Imaging 37 1106 1116 20306038 10.1007/s00259-010-1403-7 1:CAS:528:DC%2BC3cXmtV2jsbk%3D
26. JA Richter M Rodriguez J Rioja I Penuelas J Marti-Climent P Garrastachu, et al. 2010 Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment Mol Imaging Biol 12 210 217 19543774 10.1007/s11307-009-0243-y